Results 111 to 120 of about 87,895 (325)

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Effect of Albuminuria on the State of Plasma Hemostasis in Patients with Essential Hypertension

Počki, 2016
In recent decades, numerous scientific works are devoted to the study of the clinical and prognostic significance of albuminuria, methods of its detection, as well as treatment measures aimed at controlling this pathological condition.
A.I. Pastushyna, O.M. Plenova
doaj   +1 more source

Correlation Between HbA1c and Albuminuria in Type 2 Diabetes Mellitus

Majalah Kedokteran Bandung, 2020
In patients with type 2 diabetes mellitus (Type 2 DM), glycemic control plays an essential role in reducing macro- and microvascular complications. The earliest marker for diabetic nephropathy is the presence of albuminuria.
Jesika Merlin, Pusparini Pusparini
doaj   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria:Data from the CANVAS Program [PDF]

, 2019
Background If SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, peoplewith type 2 diabetes mellitus (T2DM) with higher albuminuria should benefit more.
de Zeeuw, Dick, Fulcher, Greg, Heerspink, Hiddo L., Jardine, Meg, Li, Qiang, Mahaffey, Kenneth W., Matthews, David R., Neal, Bruce, Neuen, Brendon L., Oh, Richard, Ohkuma, Toshiaki, Perkovic, Vlado   +11 more
core   +2 more sources

Detection of Fast Decliner of Diabetic Kidney Disease Using Chiral Amino Acid Profiling: A Pilot Study

Chemistry &Biodiversity, EarlyView.
We examined D‐amino acids in diabetic kidney disease (DKD). Among D‐amino acids, blood D‐serine was identified as a biomarker of DKD, and we found that short‐term change in blood D‐serine showed higher value in fast decliners in DKD patients, which meant the prognostic value of blood D‐serine in DKD.
Yosuke Hirakawa, Tomonori Kimura, Shinsuke Sakai, Masayuki Mizui, Masashi Mita, Yoshitaka Isaka, Masaomi Nangaku, Reiko Inagi   +7 more
wiley   +1 more source

Low-Grade Albuminuria Is Associated with Left Ventricular Hypertrophy and Diastolic Dysfunction in Patients with Hypertension

Kidney & Blood Pressure Research, 2019
Introduction: Microalbuminuria is a risk factor for cardiovascular morbidity and mortality in hypertensive patients. However, the relationship between low-grade albuminuria, a higher level of albuminuria below microalbuminuria threshold, and hypertension-
Tingjun Wang, Hongbin Zhong, Guili Lian, Xiaoqi Cai, Jin Gong, Chaoyi Ye, Liangdi Xie   +6 more
doaj   +1 more source

Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease. [PDF]

, 2014
The renin-angiotensin system (RAS), bone morphogenetic protein (BMP), and WNT pathways are involved in pathogenesis of diabetic kidney disease (DKD).
Afkarian, Maryam, de Boer, Ian H, Greenbaum, Carla, Himmelfarb, Jonathan, Hirsch, Irl B, Tuttle, Katherine R   +5 more
core   +1 more source

CYCLIC ALBUMINURIA. [PDF]

The Lancet, 1886
n ...
openaire   +1 more source

Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function

Clinical Pharmacology &Therapeutics, EarlyView.
Iptacopan, a first‐in‐class complement factor B inhibitor acting proximally in the alternative complement pathway, has been shown to be safe and effective for patients with complement‐mediated diseases. Iptacopan selectively binds with high affinity to factor B, a soluble, plasma‐based, hepatically produced protein.
Elise Burmeister Getz, Richard R. Stein, Martin Fink, Kenneth Kulmatycki, Irina Baltcheva, Wendy Weis, Bharti Shah, Eric Lawitz, Robert Schmouder   +8 more
wiley   +1 more source